United Therapeutics (NASDAQ:UTHR) CFO Sells $5,615,000.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 10,000 shares of the stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $561.50, for a total transaction of $5,615,000.00. Following the sale, the chief financial officer directly owned 18,876 shares in the company, valued at $10,598,874. This trade represents a 34.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

James Edgemond also recently made the following trade(s):

• On Monday, March 30th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $593.17, for a total transaction of $5,931,700.00.
• On Thursday, March 26th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $535.90, for a total transaction of $5,359,000.00.
• On Monday, March 23rd, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $527.48, for a total transaction of $5,274,800.00.

United Therapeutics Stock Performance

Shares of United Therapeutics stock traded down $5.16 on Monday, hitting $559.65. The company’s stock had a trading volume of 504,980 shares, compared to its average volume of 496,436. The company has a market capitalization of $24.53 billion, a price-to-earnings ratio of 20.06, a price-to-earnings-growth ratio of 1.63 and a beta of 0.75. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $607.89. The firm has a fifty day moving average price of $506.70 and a 200-day moving average price of $479.77.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The company had revenue of $790.20 million for the quarter, compared to the consensus estimate of $814.80 million. During the same quarter in the prior year, the business posted $6.19 earnings per share. United Therapeutics’s revenue for the quarter was up 7.4% on a year-over-year basis. As a group, analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current year.

Wall Street Analysts Forecast Growth

UTHR has been the topic of a number of research analyst reports. Royal Bank Of Canada lifted their price target on shares of United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. HC Wainwright lifted their target price on shares of United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research report on Tuesday, March 31st. Jefferies Financial Group reissued a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Finally, TD Cowen upped their price target on shares of United Therapeutics from $575.00 to $660.00 and gave the stock a “buy” rating in a research report on Monday, March 30th. Nine research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $586.00.

Institutional Trading of United Therapeutics

Several large investors have recently made changes to their positions in UTHR. Torren Management LLC purchased a new position in United Therapeutics in the 4th quarter valued at $26,000. Activest Wealth Management grew its holdings in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after buying an additional 56 shares in the last quarter. WealthCollab LLC raised its position in shares of United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 38 shares during the last quarter. Rakuten Securities Inc. lifted its stake in shares of United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 46 shares in the last quarter. Finally, Entrust Financial LLC purchased a new position in shares of United Therapeutics in the fourth quarter worth about $31,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.